Transitioning Women With Human Immunodeficiency Virus to First-Line Preferred Regimen of Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir in Sub-Saharan Africa

Thumbnail Image
Files
Transitioning Women With Human Immunodeficiency Virus to First-Line Preferred Regimen of Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir in Sub-Saharan Africa.pdf (741.04 KB)
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Clinical Infectious Diseases
Abstract
In 2019, the World Health Organization (WHO) recommended combined tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD) as the preferred first-line regimen for adults and adolescents with human immunodeficiency virus (HIV), regardless of childbearing status. Nevertheless, final eligibility is determined by local policies, which may vary from WHO recommendations. We examined TLD transition by sex across 5 HIV care programs in sub-Saharan Africa supported by the United States President's Emergency Plan for AIDS Relief (PEPFAR).
Description
Keywords
Dolutegravir, Human Immunodeficiency Virus, Tenofovir Disoproxil Fumarate
Citation
Shah, N., Esber, A., Cavanaugh, J. S., Agaba, P., Dear, N., Iroezindu, M., ... & Tanzania, M. (2022). Transitioning Women With Human Immunodeficiency Virus to First-Line Preferred Regimen of Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir in Sub-Saharan Africa. Clinical Infectious Diseases.https://doi.org/10.1093/cid/ciac555
URI
https://nru.uncst.go.ug/handle/123456789/8096
Collections
Medical and Health Sciences